Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis.

Abstract

PURPOSE:

Psoriasis patients have high risk of atherosclerosis, characterized by endothelial dysfunction. We aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-α therapy. Also, to evaluate the relationship of metabolic syndrome features with these biomarkers and the effect of anti-TNF-α therapy on these molecules.

METHODS:

Twenty-nine consecutive non-diabetic patients with moderate-to-severe psoriasis who underwent 6 months of anti-TNF-α-adalimumab therapy were studied. Metabolic and clinical evaluation was performed prior to anti-TNF-α treatment (time 0) and 6 months later. MCP-1, sE-selectin and sP-selectin serum levels were determined by ELISA.

RESULTS:

Dyslipidemic and obese patients showed higher MCP-1 levels at month 6 from the onset of anti-TNF-α therapy (p = .05 and .01, respectively). sE-selectin positively correlated with pro-inflammatory molecules such as asymmetric dimethylarginine, sP-selectin and resistin at baseline and month 6 (p < .05). sE-selectin levels significantly reduced after 6 months of therapy (p = .0006).

CONCLUSIONS:

Metabolic syndrome features are associated with endothelial activation in patients with moderate-to-severe psoriasis. Adalimumab therapy led to a reduction in sE-selectin levels, supporting the beneficial effect of anti-TNF-α therapy on mechanisms associated with the development of atherosclerosis in psoriasis.

• Authors: Fernanda Genre, Susana Armesto, Alfonso Corrales, Raquel López-Mejías, Sara Remuzgo-Martínez, Trinitario Pina, Begoña Ubilla, Verónica Mijares, José Luis Martín-Varillas, Javier Rueda-Gotor, Virginia Portilla, Trinidad Dierssen-Sotos, Marcos Antonio González-López, María Del Carmen González-Vela, Ricardo Blanco, Javier Llorca, José Luis Hernández, Miguel Ángel González-Gay
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 28 Issue 8 Pg. 726-730 (Dec 2017) ISSN: 1471-1753 [Electronic] England
• PMID: 28489469 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• Chemokine CCL2
• E-Selectin
• P-Selectin
• Resistin
• Tumor Necrosis Factor-alpha
• Adalimumab

Topics

• Adalimumab (therapeutic use)
• Adult
• Biomarkers (blood)
• Chemokine CCL2 (blood)
• Dyslipidemias (complications)
• E-Selectin (blood)
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Immunotherapy
• Male
• Middle Aged
• Obesity (complications)
• P-Selectin (blood)
• Psoriasis (complications, drug therapy, pathology)
• Resistin (blood)
• Severity of Illness Index
• Tumor Necrosis Factor-alpha (immunology)